A Study of DEG6498 in Participants With Solid Tumors

The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.

Trial Details

NCT ID
NCT07244835
Phase
PHASE1
Sponsor
Degron Therapeutics Co.
Status
RECRUITING
Cancer Type
BRAF Mutated Melanoma
Interventions
  • DEG6498
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures
  • Male and female older than or equal to 18 years of age at the time signing the informed consent form (ICF)
  • If female, must be postmenopausal, or surgically sterile, or agree to highly effective contraceptive measures to prevent pregnancy throughout treat…
  • Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests (1 serum test required) as verified by the investigator prior to start…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find BRAF Mutated Melanoma Trials on Trialify →